2268 Share Price Performance
HK$80.70
4.45 (5.84%)
12.4% undervalued intrinsic discount
HK$92.10
Fair Value
Price HK$80.70
AnalystConsensusTarget HK$92.10
Fair ValueHK$92.10
Share Pricen/a
Narrative Update • Sep 17
WuXi XDC Cayman Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
2268 Community Narratives
AN
Fair Value
·Fair Value HK$92.1 12.4% undervalued intrinsic discount
Backlog Visibility And Complex Bioconjugates Will Support A Stronger Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
WuXi XDC Cayman
12.4% undervalued intrinsic discount
Updated
Backlog Visibility And Complex Bioconjugates Will Support A Stronger Long Term Outlook
View narrativeAN
Updated 17 Sep
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
2268: Higher Future P/E Assumptions Will Support A More Optimistic Outlook
Fair Value: HK$92.1 12.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
WuXi XDC Cayman Inc. Key Details
About 2268
- Founded
- 2013
- Employees
- 3628
- CEO
- WebsiteView website
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
